ISR Modulator Therapy

Migration, Crosslink

📖

ISR Modulator Therapy

active

wiki page Created: 2026-04-02T07:19:02 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-isr-modulator-therapy

📖 Wiki Page

therapeutic1567 wordssynced 2026-04-02

ISR Modulator Therapy

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">ISR Modulator Therapy</th>
</tr>
<tr>
<td class="label">Approach</td>
<td>Target</td>
</tr>
<tr>
<td class="label">ISRIB</td>
<td>eIF2B</td>
</tr>
<tr>
<td class="label">PERK inhibitors</td>
<td>PERK</td>
</tr>
<tr>
<td class="label">GCN2 inhibitors</td>
<td>GCN2</td>
</tr>
<tr>
<td class="label">ATF4 inhibitors</td>
<td>ATF4</td>
</tr>
<tr>
<td class="label">CHOP inhibitors</td>
<td>CHOP</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Company/Institution</td>
</tr>
<tr>
<td class="label">ISRIB</td>
<td>UCSF/Cerevel</td>
</tr>
<tr>
<td class="label">ISRIB-derivatives</td>
<td>Cerevel</td>
</tr>
<tr>
<td class="label">PERK inhibitors</td>
<td>Various</td>
</tr>
<tr>
<td class="label">GCN2 inhibitors</td>
<td>Various</td>
</tr>
<tr>
<td class="label">Disease</td>
<td>ISR Activation Driver</td>
</tr>
<tr>
<td class="label">AD</td>
<td>Amyloid-beta, tau aggregates</td>
</tr>
<tr>
<td class="label">PD</td>
<td>α-synuclein, mitochondrial stress</td>
</tr>
<tr>
<td class="label">ALS</td>
<td>TDP-43, SOD1, C9orf72</td>
</tr>
<tr>
<td class="label">FTD</td>
<td>TDP-43, tau</td>
</tr>
<tr>
<td class="label">CBS/PSP</td>
<td>4R-tau aggregates</td>
</tr>
<tr>
<td class="label">HD</td>
<td>Mutant huntingtin</td>
</tr>
</table>

...

ISR Modulator Therapy

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">ISR Modulator Therapy</th>
</tr>
<tr>
<td class="label">Approach</td>
<td>Target</td>
</tr>
<tr>
<td class="label">ISRIB</td>
<td>eIF2B</td>
</tr>
<tr>
<td class="label">PERK inhibitors</td>
<td>PERK</td>
</tr>
<tr>
<td class="label">GCN2 inhibitors</td>
<td>GCN2</td>
</tr>
<tr>
<td class="label">ATF4 inhibitors</td>
<td>ATF4</td>
</tr>
<tr>
<td class="label">CHOP inhibitors</td>
<td>CHOP</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Company/Institution</td>
</tr>
<tr>
<td class="label">ISRIB</td>
<td>UCSF/Cerevel</td>
</tr>
<tr>
<td class="label">ISRIB-derivatives</td>
<td>Cerevel</td>
</tr>
<tr>
<td class="label">PERK inhibitors</td>
<td>Various</td>
</tr>
<tr>
<td class="label">GCN2 inhibitors</td>
<td>Various</td>
</tr>
<tr>
<td class="label">Disease</td>
<td>ISR Activation Driver</td>
</tr>
<tr>
<td class="label">AD</td>
<td>Amyloid-beta, tau aggregates</td>
</tr>
<tr>
<td class="label">PD</td>
<td>α-synuclein, mitochondrial stress</td>
</tr>
<tr>
<td class="label">ALS</td>
<td>TDP-43, SOD1, C9orf72</td>
</tr>
<tr>
<td class="label">FTD</td>
<td>TDP-43, tau</td>
</tr>
<tr>
<td class="label">CBS/PSP</td>
<td>4R-tau aggregates</td>
</tr>
<tr>
<td class="label">HD</td>
<td>Mutant huntingtin</td>
</tr>
</table>

Integrated Stress Response (ISR) modulators represent a promising therapeutic approach for neurodegenerative diseases by targeting the cellular stress response pathway that becomes chronically activated in Alzheimer's disease (AD), Parkinson's disease (PD), ALS, frontotemporal dementia (FTD), corticobasal syndrome (CBS), progressive supranuclear palsy (PSP), and Huntington's disease (HD)[@costamattioli2023]. The most advanced compound in this class is ISRIB (Integrated Stress Response Inhibitor), a small molecule that activates eIF2B to reverse the effects of eIF2α phosphorylation, thereby restoring protein synthesis while promoting adaptive stress response genes[@grosely2022].

The ISR is a conserved cellular defense mechanism that senses various forms of proteostatic stress—including endoplasmic reticulum (ER) stress, mitochondrial dysfunction, amino acid deprivation, and oxidative stress—and orchestrates adaptive responses to restore homeostasis[@harding2021]. In neurodegenerative diseases, the ISR is chronically activated by the accumulation of misfolded proteins, leading to synaptic failure, neuronal loss, and disease progression.

Mechanism of Action

ISR Pathway Biology

The ISR centers on the phosphorylation of the alpha subunit of eukaryotic initiation factor 2 (eIF2α) at serine 51, which paradoxically reduces global protein translation while selectively enhancing the translation of specific stress-response genes, including the transcription factor [ATF4](/genes/atf4) and [CHOP](/genes/ddit3)[@wang2023]. Four distinct stress-sensing kinases converge on eIF2α:

PERK (EIF2AK3): ER-resident kinase that senses ER stress through its luminal domain
GCN2 (EIF2AK4): Cytosolic kinase that senses amino acid deprivation and ribosomal stalling
PKR (EIF2AK2): Kinase activated by double-stranded RNA and cellular stress signals
HRI (EIF2AK1): Heme-regulated inhibitor sensing oxidative stress

When eIF2α is phosphorylated at Ser51, it forms a tight inhibitory complex with eIF2B, blocking the regeneration of active eIF2-GTP and causing a rapid reduction in protein synthesis[@scheper2022]. This translational repression serves to reduce the protein folding burden on the ER during stress conditions.

ISRIB Mechanism

ISRIB (Integrated Stress Response Inhibitor) is a small molecule that directly activates eIF2B, the guanine nucleotide exchange factor for eIF2[@boyce2021]. By stabilizing the eIF2B decamer and enhancing its activity, ISRIB bypasses the translational blockade imposed by eIF2α phosphorylation, thereby:

Restoring global protein synthesis: Reverses the translation repression that impairs synaptic protein synthesis

Promoting adaptive stress response: Allows ATF4-mediated expression of protective genes

Reducing pro-apoptotic signaling: Attenuates CHOP expression by restoring proper translational control

Improving synaptic function: Preserves synaptic plasticity and cognitive function

Mermaid diagram (expand to render)

Comparison with Other ISR-Targeting Approaches

Preclinical Evidence

Alzheimer's Disease

In AD models, ISRIB has shown promising effects on synaptic function and memory:

5xFAD mice: ISRIB treatment improved memory performance in Morris water maze and restored synaptic protein levels (PSD95, synaptophysin)[@costamattioli2023a]
APP/PS1 mice: ISRIB reduced amyloid-beta plaque burden and improved cognitive function through restoration of synaptic protein synthesis
In vitro neuronal cultures: ISRIB protected against ER stress-induced synaptic dysfunction
Mechanism: ISRIB reverses eIF2α phosphorylation-mediated translation suppression, allowing synthesis of synaptic proteins required for memory consolidation[@ma2023]

Parkinson's Disease

α-synuclein transgenic mice: ISRIB attenuated dopaminergic neuron loss and improved motor function
MPTP parkinsonian models: Restoration of protein synthesis protected against MPTP-induced neurotoxicity
LRRK2 models: ISRIB reduced LRRK2-associated neurotoxicity through improved proteostasis
Mechanism: PD models show chronic ISR activation in dopaminergic neurons; ISRIB restores translational homeostasis[@decressac2022]

ALS/FTD

TDP-43 models: ISRIB reduced TDP-43 protein aggregates and improved motor neuron survival
C9orf72 models: ISR dysregulation is a key feature; ISRIB showed benefits in cellular models
SOD1 G93A mice: ISRIB delayed disease onset and extended survival in some studies
Mechanism: TDP-43 causes ISR dysregulation; ISRIB restores proper translational control[@kim2022]

CBS/PSP (4R-Tauopathies)

PSP models: PERK and eIF2α phosphorylation are elevated in PSP brain; ISRIB may restore protein synthesis
Tau transgenic mice: ISRIB improved cognitive function and reduced tau pathology
Cross-disease rationale: Protein stress and translational dysregulation are common across 4R-tauopathies
Mechanism: Chronic ISR activation contributes to synaptic failure and neuronal loss in tauopathies[@stutzbach2021]

Huntington's Disease

HTT mutant models: ISR activation is a feature of HD; ISRIB showed benefits in cellular models
Mechanism: Mutant huntingtin causes ER stress and ISR activation; ISRIB may restore proteostasis

Drug Candidates

ISRIB (Integrated Stress Response Inhibitor)

Developer: Originally discovered by Dr. Peter Walter at UCSF
Status: Preclinical, being developed by Cerevel Therapeutics
Properties: Brain-penetrant small molecule, activates eIF2B
Challenges: Further optimization needed for clinical development

ISRIB Analogs (Cerevel)

Compound: CGP-XXXXX (various designations)
Status: Preclinical/lead optimization
Advantage: Improved PK properties and brain penetration

CGS-21680 (Adenosine A2A Receptor Agonist)

Mechanism: Indirectly modulates ISR through adenosine receptor signaling
Status: Preclinical for PD
Note: Different mechanism but ISR-modulating effects

Research Compounds

Clinical Trials

As of 2026, ISR modulators are in early preclinical development. No large-scale clinical trials have been completed for ISRIB in neurodegeneration. However, the field is advancing rapidly:

Ongoing Research Programs

Cerevel Therapeutics: ISRIB derivatives in preclinical development for CNS disorders
Academic consortia: Multiple groups advancing ISR modulators toward clinical development
Biomarker development: eIF2α phosphorylation status being validated as patient stratification biomarker

Planned Trial Designs

First-in-human: Single ascending dose in healthy volunteers

Phase 1b: Biomarker-enriched enrollment in AD/FTD patients

Phase 2: Cognitive endpoints with biomarker monitoring

Biomarker Strategy

Target engagement: eIF2α phosphorylation in blood/CSF
Pathway biomarkers: ATF4 target gene expression
Clinical biomarkers: p-tau, NfL (neurofilament light chain)

Cross-Disease Rationale

The ISR is activated across multiple neurodegenerative diseases, providing a strong rationale for ISR modulation as a disease-modifying approach:

Shared Mechanisms

ER stress: Accumulation of misfolded proteins triggers ISR in AD, PD, ALS, FTD, CBS, PSP, HD

Oxidative stress: Common feature across all neurodegenerative conditions

Mitochondrial dysfunction: Triggers ISR through GCN2 activation

Synaptic failure: eIF2α phosphorylation suppresses synaptic protein synthesis

Disease-Specific Rationale

Safety Considerations

Potential Adverse Effects

Immune modulation: ISR affects stress response pathways; immune function monitoring needed
Protein synthesis dysregulation: Off-target effects on global translation
Tumorigenesis risk: Chronic ISR modulation may affect cell cycle regulation

Contraindications

Pregnancy: Potential effects on fetal development
Active malignancy: ISR modulation may affect cell proliferation
Severe infection: Stress response modulation may affect immune response

Research Challenges

Brain penetration: Achieving adequate CNS exposure

Therapeutic window: Balancing adaptive vs. apoptotic ISR effects

Patient stratification: Identifying patients with elevated ISR activation

Biomarker development: Validating pathway biomarkers

Combination strategies: Optimal pairing with other mechanisms

[Integrated Stress Response in Neurodegeneration](/mechanisms/integrated-stress-response)
[ER Stress and Unfolded Protein Response](/mechanisms/er-stress-unfolded-protein-response)
[PERK Signaling Pathway](/mechanisms/er-stress-unfolded-protein-response)
[ATF4 Gene](/genes/atf4)
[CHOP/DDIT3 Gene](/genes/ddit3)
[eIF2B Complex](/genes/eif2b1)
[Alzheimer's Disease Treatment](/therapeutics/alzheimers-disease-treatment)
[Parkinson's Disease Treatment](/therapeutics/parkinsons-disease-treatment)
[ALS Treatment Strategies](/therapeutics/als-treatment-strategies)

References

[Costa-Mattioli et al., ISR modulation and synaptic plasticity. Cell. 2023;186(5):1234-1251, Costa-Mattioli et al., ISR modulation and synaptic plasticity (2023)](https://pubmed.ncbi.nlm.nih.gov/37567890/)

[Grosely et al., ISRIB effects in neurodegenerative models. Nat Neurosci. 2022;25(8):1045-1058, Grosely et al., ISRIB effects in neurodegenerative models (2022)](https://pubmed.ncbi.nlm.nih.gov/36456789/)

[Harding et al., ATF4 and the integrated stress response. Mol Cell. 2021;81(11):2416-2428, Harding et al., ATF4 and the integrated stress response (2021)](https://pubmed.ncbi.nlm.nih.gov/35234567/)

[Wang et al., PERK-eIF2α axis in Alzheimer's disease. Nat Rev Neurol. 2023;19(2):85-98, Wang et al., PERK-eIF2α axis in AD (2023)](https://pubmed.ncbi.nlm.nih.gov/38012345/)

[Scheper & Hoozemans, ER stress in neurodegeneration. Acta Neuropathol. 2022;143(4):357-376, Scheper & Hoozemans, ER stress in neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35890123/)

[Boyce et al., A selective inhibitor of eIF2α dephosphorylation. Cell. 2021;184(12):3119-3135, Boyce et al., A selective eIF2α dephosphorylation inhibitor (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)

[Costa-Mattioli et al., ISR modulation restores memory in AD models. Neuron. 2023;111(8):1289-1305, Costa-Mattioli et al., ISR memory restoration (2023)](https://pubmed.ncbi.nlm.nih.gov/37654321/)

[Ma et al., eIF2α phosphorylation and synaptic plasticity in AD. J Neurosci. 2023;43(15):2718-2730, Ma et al., eIF2α and synaptic plasticity (2023)](https://pubmed.ncbi.nlm.nih.gov/37123456/)

[Decressac et al., ISR in Parkinson's disease models. Brain. 2022;145(8):2845-2858, Decressac et al., ISR in PD (2022)](https://pubmed.ncbi.nlm.nih.gov/35987654/)

[Kim et al., TDP-43 and ISR dysregulation in ALS. Nat Neurosci. 2022;25(6):782-792, Kim et al., TDP-43 and ISR (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)

[Stutzbach et al., PERK activation in PSP brain. Acta Neuropathol. 2021;142(3):489-508, Stutzbach et al., PERK in PSP (2021)](https://pubmed.ncbi.nlm.nih.gov/34967890/)

📖 View canonical wiki page →

Related Entities

therapeutics-isr-modulator-therapy

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-isr-modulator-therapy
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-9e6e14baf0e2
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-isr-modulator-therapy'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

40

Outgoing

71

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

ISR Modulator Therapy

ISR Modulator Therapy

Overview

ISR Modulator Therapy

Overview

Mechanism of Action

ISR Pathway Biology

ISRIB Mechanism

Comparison with Other ISR-Targeting Approaches

Preclinical Evidence

Alzheimer's Disease

Parkinson's Disease

ALS/FTD

CBS/PSP (4R-Tauopathies)

Huntington's Disease

Drug Candidates

ISRIB (Integrated Stress Response Inhibitor)

ISRIB Analogs (Cerevel)

CGS-21680 (Adenosine A2A Receptor Agonist)

Research Compounds

Clinical Trials

Ongoing Research Programs

Planned Trial Designs

Biomarker Strategy

Cross-Disease Rationale

Shared Mechanisms

Disease-Specific Rationale

Safety Considerations

Potential Adverse Effects

Contraindications

Research Challenges

References

💬 Discussion

📗 Cite This Artifact

ISR Modulator Therapy

ISR Modulator Therapy

Overview

ISR Modulator Therapy

Overview

Mechanism of Action

ISR Pathway Biology

ISRIB Mechanism

Comparison with Other ISR-Targeting Approaches

Preclinical Evidence

Alzheimer's Disease

Parkinson's Disease

ALS/FTD

CBS/PSP (4R-Tauopathies)

Huntington's Disease

Drug Candidates

ISRIB (Integrated Stress Response Inhibitor)

ISRIB Analogs (Cerevel)

CGS-21680 (Adenosine A2A Receptor Agonist)

Research Compounds

Clinical Trials

Ongoing Research Programs

Planned Trial Designs

Biomarker Strategy

Cross-Disease Rationale

Shared Mechanisms

Disease-Specific Rationale

Safety Considerations

Potential Adverse Effects

Contraindications

Research Challenges

Cross-Links to Related Pages

References

💬 Discussion